The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy

Zhou, Haifeng; Yang, Wei; Zhou, Wei-Zhong

doi:10.1016/j.jhep.2021.12.033

Journal of Hepatology

2022

DOI: 10.1016/j.jhep.2021.12.033

|View full text |Cite

The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy

Haifeng Zhou¹,

Wei Yang²,

Wei-Zhong Zhou³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the QLQ-C30 is a life-quality questionnaire used for general cancer patients. This study showed significant changes in QLQ-C30 scores in both groups of patients compared to admission, and the observed changes were notably higher in the observation group [15] . This indicates that the therapeutic effect of sintilimab combined with bevacizumab brings a better experience for patients.…”

mentioning

confidence: 52%

Efficacy and Safety of Utilizing Sintilimab in Conjunction with Bevacizumab to Manage Advanced Hepatocellular Carcinoma

Sui,

Shi

2023

IJPS

View full text Add to dashboard Cite

To investigate the significance attributed to the utilization of sintilimab in conjunction with bevacizumab for patients suffering from advanced hepatocellular carcinoma. During the period spanning from March 2020 to March 2023, our center enrolled a 104 individuals with advanced hepatocellular carcinoma, who were then allocated into either the observation group (treated with sintilimab and bevacizumab) or the control group (treated with sintilimab). Safety was the primary outcome of this study, evaluated by monitoring and recording adverse events. The QLQ-C30 questionnaire was utilized to evaluate healthrelated life quality and hepatocellular carcinoma-specific symptoms, and overall survival rate was the secondary outcome. The two groups exhibited similar baseline characteristics, without any significant differences (p>0.05). The two groups did not significantly differ in terms of the incidence of each adverse event; however, the observation group had a significantly higher overall incidence rate of adverse events than the control group (p<0.05). The QLQ-C30 scores of both groups showed significant improvement compared to baseline, with more significant improvements observed in the observation group in terms of overall health status, physical functioning and emotional functioning (p<0.05). In terms of overall survival rate, the observation group outperformed the control group significantly. In conclusion, when treating individuals with advanced hepatocellular carcinoma, the joined administration of sintilimab and bevacizumab may result in a higher frequency of adverse events. Nevertheless, this treatment approach offers the benefits of improved overall survival rate and enhanced quality of life, underscoring its considerable clinical value and suitability for promotion.

show abstract

mentioning

confidence: 52%

Efficacy and Safety of Utilizing Sintilimab in Conjunction with Bevacizumab to Manage Advanced Hepatocellular Carcinoma

Sui,

Shi

2023

IJPS

View full text Add to dashboard Cite

show abstract

Reply to: “The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy”

Scheiner¹,

Pinter²

2022

Journal of Hepatology

View full text Add to dashboard Cite

Validation of the CRAFITY score for predicting prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization combined with systemic therapy

Zhou,

Ren,

et al. 2024

Journal of Interventional Medicine

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy

Cited by 3 publications

References 8 publications

Efficacy and Safety of Utilizing Sintilimab in Conjunction with Bevacizumab to Manage Advanced Hepatocellular Carcinoma

Efficacy and Safety of Utilizing Sintilimab in Conjunction with Bevacizumab to Manage Advanced Hepatocellular Carcinoma

Reply to: “The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy”

Validation of the CRAFITY score for predicting prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization combined with systemic therapy

Contact Info

Product

Resources

About